Articles by Louis Garguilo

  1. Virtual And Variable: Two Visions For Biopharma Outsourcing In 2018 12/7/2017

    Deborah Dunsire, CEO of XTuit Pharmaceuticals; and Robert Discordia, executive director, global product development & supply procurement for Bristol-Myers Squibb discuss new approaches to external partnerships in pharma.

  2. Boehringer Ingelheim And The Two Sides Of Biologics Outsourcing 9/28/2017

    Jens Vogel, President & CEO, BI Fremont Inc., can’t help seeing two sides to most everything associated with the development and manufacturing of biologics. For example, he says we are in an era that at the same time can be dubbed “Death of the Blockbuster” and “Return of the Blockbuster.”

  3. Rising Out Of Takeda's Reorganization: New Materials & Innovation 8/9/2017

    “You don’t have time to invest in basic research and wait 10 years. You have to go find individuals and companies doing exciting research, engage them, and progress those new technologies through collaborations and funding,” explains Takeda’s Vincent Ling.